Cost-Effectiveness of the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Versus Lower-Valent Alternatives in Filipino Infants

被引：0
|
作者：
Rajeev Dhere
Vistasp Sethna
Hitesh Malviya
Rajeshwari Adhiseshan
机构：
[1] Serum Institute of India Private Limited,
来源：
Infectious Diseases and Therapy | 2022年 / 11卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1297 / 1299
页数：2
相关论文
共 50 条
  • [31] The Cost-Effectiveness of 13-Valent Pneumococcal Conjugate Vaccine in Seven Chinese Cities
    Li, Yan
    Wang, Huaqing
    Furnback, Wesley
    Wang, Bruce C. M.
    Zhu, Shuiqing
    Dong, Peng
    VACCINES, 2021, 9 (11)
  • [32] Cost-effectiveness of 13-valent pneumococcal conjugate vaccine: Germany, Greece, and The Netherlands
    Strutton, David R.
    Farkouh, Raymond A.
    Earnshaw, Stephanie R.
    Hwang, Sharon
    Theidel, Ulrike
    Kontodimas, Stathis
    Klok, Rogier
    Papanicolaou, Sotiria
    JOURNAL OF INFECTION, 2012, 64 (01) : 54 - 67
  • [33] Effectiveness data on prevention of COPD exacerbations with 13-valent pneumococal conjugate vaccine (PCV13)
    Hernandez, Miguel Angel
    Boscan, Alexis Morales
    Sierra, Vanesa Hidalgo
    Zubizarreta, Marco Lopez
    Perez, Rosa Cordovilla
    Sanchez, Soraya Jodra
    Ferrero, Miguel Barrueco
    Ruiz, Jose Maria Gonzalez
    VelaZquez, Virginia Guevara
    EUROPEAN RESPIRATORY JOURNAL, 2017, 50
  • [34] Cost-effectiveness of 13-valent pneumococcal conjugate vaccination in Mongolia
    Sundaram, Neisha
    Chen, Cynthia
    Yoong, Joanne
    Luvsan, Munkh-Erdene
    Fox, Kimberley
    Sarankhuu, Amarzaya
    La Vincente, Sophie
    Jit, Mark
    VACCINE, 2017, 35 (07) : 1055 - 1063
  • [35] A cost-effectiveness analysis of vaccinating older adults with the 23-valent pneumococcal polysaccharide vaccine (PPV23) compared to no vaccination, the 13-valent pneumococcal conjugate vaccine (PCV13), or PCV13 followed by PPV23 in Colombia
    Prieto, E.
    Jiang, Y.
    Yang, X.
    Graham, J. B.
    Monsanto, H.
    Ruiz, J.
    Beltran, C.
    Rojas, M.
    INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2018, 73 : 13 - 13
  • [36] COST-EFFECTIVENESS ANALYSIS OF SEQUENTIAL VACCINATION OF 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE (PCV13) AND 23-VALENT PNEUMOCOCCAL POLYSACCHARIDE VACCINE (PPSV23) ON ADULT POPULATION IN SOUTH KOREA
    Park, D.
    Kang, S.
    VALUE IN HEALTH, 2017, 20 (09) : A788 - A788
  • [37] Cost-Effectiveness of a 10-Versus 13-Valent Pneumococcal Conjugate Vaccine in Denmark and Sweden
    Klok, Rogier M.
    Lindkvist, Rose-Marie
    Ekelund, Mats
    Farkouh, Raymond A.
    Strutton, David R.
    CLINICAL THERAPEUTICS, 2013, 35 (02) : 119 - 134
  • [38] COST-EFFECTIVENESS OF 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINATION IN KAZAKHSTAN
    Bektur, C.
    Nurgozhin, T.
    VALUE IN HEALTH, 2015, 18 (03) : A106 - A106
  • [39] Public health and economic impact of the 13-valent pneumococcal conjugate vaccine (PCV13) in the United States
    Rubin, Jaime L.
    McGarry, Lisa J.
    Strutton, David R.
    Klugman, Keith P.
    Pelton, Stephen I.
    Gilmore, Kristen E.
    Weinstein, Milton C.
    VACCINE, 2010, 28 (48) : 7634 - 7643
  • [40] 13-Valent pneumococcal conjugate vaccine (PCV13) serotypes in adults with community acquired pneumonia in Taiwan
    Chang, S. C.
    Li, C. T.
    Cheng, S. L.
    Gray, S.
    Gonzalez, E.
    Pride, M.
    Sebastian, S.
    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2015, 45 : S119 - S119
12345